Nuclear Receptor ROR-Gamma (Nuclear Receptor RZR-Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR-Related Orphan Receptor C or Retinoid-Related Orphan Receptor-Gamma or RORC) - Pipeline Review, H1 2016

Published: May, 2016 | Pages: 97 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Nuclear Receptor ROR-Gamma (Nuclear Receptor RZR-Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR-Related Orphan Receptor C or Retinoid-Related Orphan Receptor-Gamma or RORC) - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Nuclear Receptor ROR-Gamma (Nuclear Receptor RZR-Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR-Related Orphan Receptor C or Retinoid-Related Orphan Receptor-Gamma or RORC) - Pipeline Review, H1 2016', provides in depth analysis on Nuclear Receptor ROR-Gamma (Nuclear Receptor RZR-Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR-Related Orphan Receptor C or Retinoid-Related Orphan Receptor-Gamma or RORC) targeted pipeline therapeutics. 

The report provides comprehensive information on the Nuclear Receptor ROR-Gamma (Nuclear Receptor RZR-Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR-Related Orphan Receptor C or Retinoid-Related Orphan Receptor-Gamma or RORC), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Nuclear Receptor ROR-Gamma (Nuclear Receptor RZR-Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR-Related Orphan Receptor C or Retinoid-Related Orphan Receptor-Gamma or RORC) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Nuclear Receptor ROR-Gamma (Nuclear Receptor RZR-Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR-Related Orphan Receptor C or Retinoid-Related Orphan Receptor-Gamma or RORC)
- The report reviews Nuclear Receptor ROR-Gamma (Nuclear Receptor RZR-Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR-Related Orphan Receptor C or Retinoid-Related Orphan Receptor-Gamma or RORC) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Nuclear Receptor ROR-Gamma (Nuclear Receptor RZR-Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR-Related Orphan Receptor C or Retinoid-Related Orphan Receptor-Gamma or RORC) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Nuclear Receptor ROR-Gamma (Nuclear Receptor RZR-Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR-Related Orphan Receptor C or Retinoid-Related Orphan Receptor-Gamma or RORC) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Nuclear Receptor ROR-Gamma (Nuclear Receptor RZR-Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR-Related Orphan Receptor C or Retinoid-Related Orphan Receptor-Gamma or RORC) targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Nuclear Receptor ROR-Gamma (Nuclear Receptor RZR-Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR-Related Orphan Receptor C or Retinoid-Related Orphan Receptor-Gamma or RORC)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Nuclear Receptor ROR-Gamma (Nuclear Receptor RZR-Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR-Related Orphan Receptor C or Retinoid-Related Orphan Receptor-Gamma or RORC) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope

 Table of Contents

Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Nuclear Receptor ROR-Gamma (Nuclear Receptor RZR-Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR-Related Orphan Receptor C or Retinoid-Related Orphan Receptor-Gamma or RORC) Overview 10
Therapeutics Development 11
Nuclear Receptor ROR-Gamma (Nuclear Receptor RZR-Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR-Related Orphan Receptor C or Retinoid-Related Orphan Receptor-Gamma or RORC) - Products under Development by Stage of Development 11
Nuclear Receptor ROR-Gamma (Nuclear Receptor RZR-Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR-Related Orphan Receptor C or Retinoid-Related Orphan Receptor-Gamma or RORC) - Products under Development by Therapy Area 12
Nuclear Receptor ROR-Gamma (Nuclear Receptor RZR-Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR-Related Orphan Receptor C or Retinoid-Related Orphan Receptor-Gamma or RORC) - Products under Development by Indication 13
Nuclear Receptor ROR-Gamma (Nuclear Receptor RZR-Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR-Related Orphan Receptor C or Retinoid-Related Orphan Receptor-Gamma or RORC) - Pipeline Products Glance 15
Late Stage Products 15
Early Stage Products 16
Unknown Stage Products 17
Nuclear Receptor ROR-Gamma (Nuclear Receptor RZR-Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR-Related Orphan Receptor C or Retinoid-Related Orphan Receptor-Gamma or RORC) - Products under Development by Companies 18
Nuclear Receptor ROR-Gamma (Nuclear Receptor RZR-Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR-Related Orphan Receptor C or Retinoid-Related Orphan Receptor-Gamma or RORC) - Products under Development by Universities/Institutes 25
Nuclear Receptor ROR-Gamma (Nuclear Receptor RZR-Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR-Related Orphan Receptor C or Retinoid-Related Orphan Receptor-Gamma or RORC) - Therapeutics Assessment 27
Assessment by Monotherapy/Combination Products 27
Assessment by Mechanism of Action 28
Assessment by Route of Administration 30
Assessment by Molecule Type 32
Nuclear Receptor ROR-Gamma (Nuclear Receptor RZR-Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR-Related Orphan Receptor C or Retinoid-Related Orphan Receptor-Gamma or RORC) - Companies Involved in Therapeutics Development 33
4SC AG 33
Advinus Therapeutics Ltd. 34
Arrien Pharmaceuticals, LLC 35
Aurigene Discovery Technologies Limited 36
Biogen, Inc. 37
Brickell Biotech, Inc. 38
Bristol-Myers Squibb Company 39
Celgene Corporation 40
Genentech, Inc. 41
Genfit SA 42
GlaxoSmithKline Plc 43
Hanmi Pharmaceuticals, Co. Ltd. 44
Karo Bio AB 45
Lead Pharma Holding B.V. 46
Nuevolution AB 47
Phenex Pharmaceuticals AG 48
Reata Pharmaceuticals, Inc. 49
Teijin Pharma Limited 50
Visionary Pharmaceuticals, Inc. 51
Vitae Pharmaceuticals, Inc. 52
Nuclear Receptor ROR-Gamma (Nuclear Receptor RZR-Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR-Related Orphan Receptor C or Retinoid-Related Orphan Receptor-Gamma or RORC) - Drug Profiles 53
ARN-6039 - Drug Profile 53
Product Description 53
Mechanism Of Action 53
R&D Progress 53
BBI-6000 - Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
GSK-2981278 - Drug Profile 56
Product Description 56
Mechanism Of Action 56
R&D Progress 56
INV-17 - Drug Profile 57
Product Description 57
Mechanism Of Action 57
R&D Progress 57
Small Molecule to Agonize ROR-Gamma for Inflammation and Oncology - Drug Profile 58
Product Description 58
Mechanism Of Action 58
R&D Progress 58
Small Molecule to Antagonize RAR-Related Orphan Receptor Gamma for Psoriasis - Drug Profile 59
Product Description 59
Mechanism Of Action 59
R&D Progress 59
Small Molecule to Antagonize ROR-Gamma for Multiple Sclerosis - Drug Profile 60
Product Description 60
Mechanism Of Action 60
R&D Progress 60
Small Molecule to Inhibit RORgammat for CNS, Autoimmune and Gastrointestinal Disorders - Drug Profile 61
Product Description 61
Mechanism Of Action 61
R&D Progress 61
Small Molecules to Agonize RAR-Related Orphan Receptor Gamma for Autoimmune Disorders and Inflammation - Drug Profile 62
Product Description 62
Mechanism Of Action 62
R&D Progress 62
Small Molecules to Agonize ROR gamma for Breast Cancer - Drug Profile 63
Product Description 63
Mechanism Of Action 63
R&D Progress 63
Small Molecules to Agonize ROR-Gamma for Autoimmune Disease - Drug Profile 65
Product Description 65
Mechanism Of Action 65
R&D Progress 65
Small Molecules to Agonize ROR-Gamma for Oncology - Drug Profile 66
Product Description 66
Mechanism Of Action 66
R&D Progress 66
Small Molecules to Antagonize ROR-Gamma for Autoimmune Disorders - Drug Profile 67
Product Description 67
Mechanism Of Action 67
R&D Progress 67
Small Molecules to Antagonize ROR-Gamma T for Autoimmune Disorders - Drug Profile 68
Product Description 68
Mechanism Of Action 68
R&D Progress 68
Small Molecules to Antagonize RORc for Autoimmune Diseases and Inflammation - Drug Profile 69
Product Description 69
Mechanism Of Action 69
R&D Progress 69
Small Molecules to Antagonize RORC for Immunology, Multiple Sclerosis and Non-Alcoholic Steatohepatitis - Drug Profile 70
Product Description 70
Mechanism Of Action 70
R&D Progress 70
Small Molecules to Antagonize RORC for Multiple Sclerosis, Immunology and Non-Alcoholic Steatohepatitis - Drug Profile 71
Product Description 71
Mechanism Of Action 71
R&D Progress 71
Small Molecules to Inhibit ROR gamma-t for Autoimmune Diseases - Drug Profile 72
Product Description 72
Mechanism Of Action 72
R&D Progress 72
Small Molecules to Inhibit ROR gamma-t for Multiple Sclerosis and Rheumatoid Arthritis - Drug Profile 73
Product Description 73
Mechanism Of Action 73
R&D Progress 73
Small Molecules to Inhibit ROR-Gamma for Inflammation - Drug Profile 74
Product Description 74
Mechanism Of Action 74
R&D Progress 74
Small Molecules to Inhibit ROR-Gamma T for Autoimmune Disorders and Inflammation - Drug Profile 75
Product Description 75
Mechanism Of Action 75
R&D Progress 75
Small Molecules to Target ROR Gamma - Drug Profile 76
Product Description 76
Mechanism Of Action 76
R&D Progress 76
Small Molecules to Target ROR gamma for Autoimmune Diseases - Drug Profile 77
Product Description 77
Mechanism Of Action 77
R&D Progress 77
SR-1001 - Drug Profile 78
Product Description 78
Mechanism Of Action 78
R&D Progress 78
TGFTX-1 - Drug Profile 79
Product Description 79
Mechanism Of Action 79
R&D Progress 79
TMP-778 - Drug Profile 80
Product Description 80
Mechanism Of Action 80
R&D Progress 80
VPR-66 - Drug Profile 81
Product Description 81
Mechanism Of Action 81
R&D Progress 81
VTP-43742 - Drug Profile 82
Product Description 82
Mechanism Of Action 82
R&D Progress 82
Nuclear Receptor ROR-Gamma (Nuclear Receptor RZR-Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR-Related Orphan Receptor C or Retinoid-Related Orphan Receptor-Gamma or RORC) - Dormant Projects 84
Nuclear Receptor ROR-Gamma (Nuclear Receptor RZR-Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR-Related Orphan Receptor C or Retinoid-Related Orphan Receptor-Gamma or RORC) - Discontinued Products 85
Nuclear Receptor ROR-Gamma (Nuclear Receptor RZR-Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR-Related Orphan Receptor C or Retinoid-Related Orphan Receptor-Gamma or RORC) - Featured News & Press Releases 86
Mar 16, 2016: Vitae Pharmaceuticals Achieves Proof-of-Concept with First-in-Class RORyt Inhibitor in Moderate to Severe Psoriasis 86
Nov 18, 2015: Vitae Pharmaceuticals Announces Positive Top-Line Results From a Phase 1 Multiple Ascending Dose Trial of VTP-43742 87
Nov 03, 2015: Lycera Announces Progress in Immuno-Oncology Program to be Presented at Society for Immunotherapy of Cancer (SITC) 2015 Annual Meeting 87
Nov 02, 2015: Lead Pharma Achieves first Milestone for Development of Autoimmune Diseases Treatments in Research Collaboration with Sanofi 88
Sep 29, 2015: Vitae Pharmaceuticals Initiates Second Part of a Phase 1 Multiple Ascending Dose Study of VTP-43742 in Psoriatic Patients 89
Sep 08, 2015: Vitae Pharmaceuticals Announces Positive Top-Line Results From Initial Phase 1 Study of First-in-Class RORyt Inhibitor VTP-43742 in Autoimmune Disorders 89
Aug 10, 2015: Vitae Pharmaceuticals Announces Initiation of a Phase 1 Multiple Ascending Dose Study of VTP-43742 in Autoimmune Disorders 90
Aug 05, 2015: Aurigene to Present its RORg Inverse Agonist Program at World Congress on Inflammation, 2015 91
Jun 29, 2015: Vitae Pharmaceuticals Announces Initiation of a Phase 1 Single Ascending Dose Study of VTP-43742 in Autoimmune Disorders 91
Apr 16, 2015: Vitae Pharmaceuticals to Present at Keystone Symposia on Mechanisms of Pro-Inflammatory Diseases 91
Mar 17, 2015: New Compound Prevents Type 1 Diabetes in Animal Models�Before It Begins 92
Feb 09, 2015: Lycera Announces Research Showing Promising Anti-Cancer Activity of Novel, Oral Immunotherapy Candidates 93
Jan 05, 2015: Lycera Scientists Identify Endogenous Agonists for ROR that control Th17 Cell Differentiation 93
Nov 07, 2014: Lycera Announces Research Showing Novel, Oral Immunotherapy Possesses Potent Single Agent Anti-Cancer Activity 94
Nov 05, 2014: Innovimmune to Present Superior Preclinical Therapeutic Efficacy Results in Rheumatoid Arthritis of Its INV-17 ROR Gamma t Inhibitor Program at the 2014 American College of Rheumatology Annual Meeting 95
Appendix 96
Methodology 96
Coverage 96
Secondary Research 96
Primary Research 96
Expert Panel Validation 96
Contact Us 96
Disclaimer 97

List of Tables

Number of Products under Development for, H1 2016 11
Number of Products under Development by Therapy Area, H1 2016 12
Number of Products under Development by Indication, H1 2016 14
Comparative Analysis by Late Stage Development, H1 2016 15
Comparative Analysis by Early Stage Products, H1 2016 16
Comparative Analysis by Unknown Stage Development, H1 2016 17
Number of Products under Development by Companies, H1 2016 18
Products under Development by Companies, H1 2016 19
Products under Development by Companies, H1 2016 (Contd..1) 20
Products under Development by Companies, H1 2016 (Contd..2) 22
Products under Development by Companies, H1 2016 (Contd..3) 24
Number of Products under Investigation by Universities/Institutes, H1 2016 25
Products under Investigation by Universities/Institutes, H1 2016 26
Assessment by Monotherapy/Combination Products, H1 2016 27
Number of Products by Stage and Mechanism of Action, H1 2016 29
Number of Products by Stage and Route of Administration, H1 2016 31
Number of Products by Stage and Molecule Type, H1 2016 32
Pipeline by 4SC AG, H1 2016 33
Pipeline by Advinus Therapeutics Ltd., H1 2016 34
Pipeline by Arrien Pharmaceuticals, LLC, H1 2016 35
Pipeline by Aurigene Discovery Technologies Limited, H1 2016 36
Pipeline by Biogen, Inc., H1 2016 37
Pipeline by Brickell Biotech, Inc., H1 2016 38
Pipeline by Bristol-Myers Squibb Company, H1 2016 39
Pipeline by Celgene Corporation, H1 2016 40
Pipeline by Genentech, Inc., H1 2016 41
Pipeline by Genfit SA, H1 2016 42
Pipeline by GlaxoSmithKline Plc, H1 2016 43
Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H1 2016 44
Pipeline by Karo Bio AB, H1 2016 45
Pipeline by Lead Pharma Holding B.V., H1 2016 46
Pipeline by Nuevolution AB, H1 2016 47
Pipeline by Phenex Pharmaceuticals AG, H1 2016 48
Pipeline by Reata Pharmaceuticals, Inc., H1 2016 49
Pipeline by Teijin Pharma Limited, H1 2016 50
Pipeline by Visionary Pharmaceuticals, Inc., H1 2016 51
Pipeline by Vitae Pharmaceuticals, Inc., H1 2016 52
Dormant Projects, H1 2016 84
Discontinued Products, H1 2016 85